PlainMeds drug rankings
Most Hospitalization Reports
All tracked drugs ranked by FAERS reports involving hospitalization.
Data updated 2026-05-15
- 524
- Drugs ranked
- 203,341
- Top: Aspirin
- 45,226
- #50: Citalopram
This board versus the other map
Ustekinumab is NADAC unit-cost #1 of 572 at $26,794.63/unit at FAERS #78 of 524 ≠ Adalimumab FAERS report-volume #1 of 524 at 695,825 at NADAC #8 of 572. Testosterone is a third map: recall-count #1 of 202 (28 actions).
- #1
- Ustekinumab NADAC
- $26,794.63
- per unit
- #1
- Adalimumab FAERS
- 695,825
- reports (not danger)
According to CMS NADAC and FDA FAERS compiled on /methodology. The table below is this board only. Report volume is not per-patient risk, and this page is not medical advice.
Verify with FDA → · CMS NADAC pricing →
What This Ranking Tells Us
Hospitalization reports in FAERS indicate cases where a drug-associated adverse event led to or extended a hospital stay. Widely prescribed medications naturally accumulate more reports. Blood thinners, insulin, and cardiovascular drugs often top this list because their therapeutic effects require careful dosing, too much or too little can require emergency intervention. These reports help FDA identify drugs that may benefit from improved dosing guidelines or additional monitoring requirements.
Top 12 by Hospital Reports
All tracked drugs ranked by FAERS reports involving hospitalization.
- aspirin
aspirin
203,341 Hospital Reports
- furosemide
furosemide
190,901 Hospital Reports
- prednisone
prednisone
166,315 Hospital Reports
- acetaminophen
acetaminophen
150,224 Hospital Reports
- adalimumab
adalimumab
146,638 Hospital Reports
- omeprazole
omeprazole
122,601 Hospital Reports
- metformin
metformin
122,330 Hospital Reports
- methotrexate
methotrexate
115,535 Hospital Reports
- pantoprazole
pantoprazole
111,504 Hospital Reports
- dexamethasone
dexamethasone
109,720 Hospital Reports
- amlodipine
amlodipine
104,040 Hospital Reports
- gabapentin
gabapentin
103,305 Hospital Reports
What this shows aspirin leads at 203,341, ahead of furosemide and prednisone.
| # | Drug | Hospital Reports |
|---|---|---|
| 1 | aspirin | 203,341 |
| 2 | furosemide | 190,901 |
| 3 | prednisone | 166,315 |
| 4 | acetaminophen | 150,224 |
| 5 | adalimumab | 146,638 |
| 6 | omeprazole | 122,601 |
| 7 | metformin | 122,330 |
| 8 | methotrexate | 115,535 |
| 9 | pantoprazole | 111,504 |
| 10 | dexamethasone | 109,720 |
| 11 | amlodipine | 104,040 |
| 12 | gabapentin | 103,305 |
| 13 | rivaroxaban | 102,060 |
| 14 | ergocalciferol | 98,409 |
| 15 | metoprolol | 96,962 |
| 16 | lisinopril | 95,486 |
| 17 | simvastatin | 94,740 |
| 18 | clopidogrel | 88,784 |
| 19 | levothyroxine | 88,368 |
| 20 | folic acid | 87,188 |
| 21 | ibuprofen | 81,556 |
| 22 | prednisolone | 79,445 |
| 23 | pregabalin | 74,751 |
| 24 | allopurinol | 74,277 |
| 25 | lorazepam | 72,527 |
| 26 | atorvastatin | 68,513 |
| 27 | quetiapine | 67,436 |
| 28 | etanercept | 65,552 |
| 29 | alprazolam | 64,280 |
| 30 | spironolactone | 64,112 |
| 31 | ramipril | 62,948 |
| 32 | insulin glargine | 62,916 |
| 33 | lansoprazole | 62,821 |
| 34 | infliximab | 62,267 |
| 35 | rosuvastatin | 60,611 |
| 36 | warfarin | 57,230 |
| 37 | methylprednisolone | 53,959 |
| 38 | carvedilol | 53,070 |
| 39 | clozapine | 53,005 |
| 40 | oxycodone | 49,832 |
| 41 | losartan | 48,929 |
| 42 | hydrochlorothiazide | 48,508 |
| 43 | potassium chloride | 48,372 |
| 44 | levetiracetam | 47,411 |
| 45 | atenolol | 47,314 |
| 46 | ondansetron | 47,077 |
| 47 | clonazepam | 46,031 |
| 48 | olanzapine | 45,342 |
| 49 | zolpidem | 45,304 |
| 50 | citalopram | 45,226 |
Primary source: FDA Adverse Event Reporting System (FAERS). Supplementary labeling: FDA Drug Labels (SPL). These rankings are source-record indexes and do not provide medical, treatment, substitution, or medication-change directions.
Frequently Asked Questions
What does a hospitalization report in FAERS mean?
It means an adverse event report included hospitalization (initial or prolonged) as a serious outcome. The hospitalization may have been caused by the drug, an underlying condition, or a combination. FAERS does not determine causality, it documents associations for FDA to investigate.
Are drugs with more hospitalization reports less safe?
Not necessarily. Drugs prescribed to millions of people or to severely ill populations will naturally have more hospitalization reports. A per-prescription hospitalization rate would be more informative. These rankings are useful for identifying which drugs require the most post-marketing surveillance.
Reading the Most Hospitalization Reports
This table ranks 50 drugs by hospital reports, sourced from FDA Adverse Event Reporting System (FAERS). The current leader is aspirin at 203,341, followed by furosemide and prednisone. Each row links to a full drug profile so readers can move from headline number to the underlying FDA data, labeling, FAERS reports, recalls, pricing, and shortage status, that explains why a particular drug sits where it does.
Hospitalization reports in FAERS indicate cases where a drug-associated adverse event led to or extended a hospital stay. Widely prescribed medications naturally accumulate more reports. Blood thinners, insulin, and cardiovascular drugs often top this list because their therapeutic effects require careful dosing, too much or too little can require emergency intervention. These reports help FDA identify drugs that may benefit from improved dosing guidelines or additional monitoring requirements.
Rankings are diagnostic, not prescriptive. Absolute numbers are shaped by exposure volume, reporting practices, and data-collection methodology, so a drug near the top is not automatically "worse" than a drug near the bottom, it may simply be older, more widely prescribed, or manufactured by firms with more visible reporting. Context from FDA Adverse Event Reporting System (FAERS) updates continuously, which means the relative order here can change from one refresh to the next. Rankings on this page are for educational research only and must not be used as a substitute for medical advice from a licensed clinician.
Explore More Rankings
These rankings are for informational purposes only and do not constitute medical advice. They copy CMS NADAC and FDA FAERS/Enforcement Report extracts; they do not tell anyone which medicine to take. See methodology and guides.
Read our methodology - how this data is sourced, computed, and verified.
Source: FDA Adverse Event Reporting System (FAERS)
See our methodology for how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.